MET and pneumonitis: The FDA approved capmatinib for adults with metastatic non-small cell lung cancer (mNSCLC) with MET exon 14 skipping mutations based on a clinical trial in which capmatinib was permanently discontinued in 16% of mNSCLC patients due to an adverse reaction, most commonly pneumonitis (1.8%), peripheral edema (1.8%) and fatigue (1.5%) [50], providing initial insights into potential toxicities in the pediatric population.